Abstract:Xylazine, an α2 adrenergic receptor agonist, was originally designated for veterinary multipurpose use as a sedative, analgesic, and muscle relaxant. Illicit use of xylazine started in Puerto Rico in the 2000s, with it becoming mixed as an adulterant with other drugs of abuse. Fentanyl-xylazine combinations began to proliferate in the northeastern US, with xylazine found in 90% of fentanyl samples, which was increasingly associated with higher percentages of fentanyl-associated deaths ( 1 ). The fentanyl-xylazine combination has complicated treatment of opioid use disorder (OUD), as high doses of xylazine can mimic some effects of opioids without being countered by naloxone/naltrexone administration ( 2 , 3 ). Chronic injection of drugs laced with xylazine can also lead to tissue necrosis at the injection site, which may result in amputation and/or death ( 2 ). Preclinical work in animals investigating fentanyl-xylazine interactions is limited, and given xylazine's impact on the OUD public health emergency, fundamental questions remain regarding how xylazine and fentanyl affect brain neurochemistry and OUD ( 4 ). We tested the effects of xylazine, with or without fentanyl, using fiber photometry to monitor dopamine release in the nucleus accumbens (NAc) of mice expressing the GRABDA2M sensor. This sensor has dopamine binding and modified EGFP domains, and it fluoresces relative to synaptic dopamine levels. Xylazine treatment (5 mg/kg, i.p.) significantly increased fluorescence, which peaked approximately 50 minutes after injection, suggesting increased dopamine release in the NAc (Figure 1A). In contrast, locomotor activity dropped to very low levels immediately after xylazine injection and remained significantly lowered throughout the session (Figure 1B). While reduced locomotor activity was expected considering the sedative properties of xylazine, the increase in extracellular dopamine was not anticipated. Xylazine induces dopamine release through an α2 adrenergic receptor effect and potentiates the neurochemical effects of fentanyl. ( A ) Xylazine (red arrow) significantly induced dopamine release ( n = 6/group; repeated measures [RM] 1-way ANOVA main effect of time F (44,220) = 4.499, **** P < 0.0001) and ( B ) reduced locomotor activity ( n = 6/group; RM 1-way ANOVA main effect of time F (44,220) = 3.452, **** P < 0.0001). ( C ) Pretreatment with the α2 adrenergic receptor antagonist atipamezole (red arrow) significantly blocked the effects of xylazine (blue arrow) on dopamine release ( n = 6/group; 2-way RM-ANOVA main effect of treatment F (1, 10) = 21.79, *** P = 0.0009; treatment × time interaction F (34, 340) = 12.19, **** P < 0.0001 analyzing 70 minutes after atipamezole and xylazine treatments). ( D ) Atipamezole partially attenuated the effects on locomotor activity ( n = 6/group; 2-way RM-ANOVA main effect of treatment F (1,10) = 18.60, ** P = 0.0015; treatment × time interaction F (34,340) = 1.872, ** P = 0.0030). ( E ) Fentanyl treatment (red arrow) induced significant dopamine release ( n = 6/group; 1-way RM-ANOVA main effect of time F (44, 220) = 34.52, **** P < 0.0001) and locomotor activity ( n = 6/group; RM 1-way ANOVA main effect of time F (44,220) = 1.828, ** P = 0.0026) ( F ). ( G ) Coadministration of fentanyl and xylazine (red arrow) significantly augmented the effects of fentanyl alone on dopamine release ( n = 6/group;2-way RM-ANOVA main effect of treatment F (1,10) = 14.01, ** P = 0.0038, and a significant interaction of treatment × time F (44, 440) = 9.751, **** P < 0.0001), while locomotor activity was reduced compared to fentanyl alone ( n = 4 combo, n = 6 fentanyl; 2-way RM-ANOVA main effect of treatment F (1,8) = 60.65, **** P < 0.0001; treatment × time interaction F (44,352) = 2.343, **** P < 0.0001) ( H ). All error bars are SEM. To determine whether the effect of xylazine on dopamine was mediated directly by α2 adrenergic receptor signaling, we pretreated mice with a selective α2 adrenergic receptor antagonist. Atipamezole pretreatment (2 mg/kg, i.p.) 20 minutes prior to xylazine (5 mg/kg, i.p.) attenuated the effects of xylazine on dopamine release, confirming that this potential effect of xylazine on dopamine is dependent on α2 adrenergic signaling (Figure 1C). Locomotor activity was also significantly higher in these sessions compared with that of xylazine alone, consistent with α2 adrenergic–mediated sedative effects of xylazine (Figure 1D). Opioids target dopamine -Abstract Truncated-

Xylazine: A Drug Adulterant of Clinical Concern

Xylazine Adulteration of the Heroin-Fentanyl Drug Supply : A Narrative Review

Xylazine Adulteration in Illicit Fentanyl: A Threat to Public Health

National Institute on Drug Abuse Clinical Trials Network Meeting Report: Managing Patients Exposed to Xylazine-Adulterated Opioids in Emergency, Hospital and Addiction Care Settings

Xylazine in the Opioid Epidemic: A Systematic Review of Case Reports and Clinical Implications

Xylazine Abuse, The Growing Risk: A Review of Its Effects, Upsurge Use and Associated Fatalities in the USA and Puerto Rico.

Xylazine Spreads Across the US: A Growing Component of the Increasingly Synthetic and Polysubstance Overdose Crisis

Opioid overdoses involving xylazine in emergency department patients: a multicenter study

Xylazine in the Unregulated Drug Market: An Integrative Review of Its Prevalence, Health Impacts, and Detection and Intervention Challenges in the United States

The New Stealth Drug on the Street: A Narrative Review of Xylazine as a Street Drug

Xylazine Exacerbates Fentanyl-Induced Respiratory Depression and Bradycardia

Xylazine detected in unregulated opioids and drug administration equipment in Toronto, Canada: clinical and social implications

Xylazine-Induced Necrotic Skin Ulcers in a Fentanyl-Injecting Individual in South Florida, United States: A Case Report

Unmasking the Dual Threat of Fentanyl and Xylazine Abuse in America

Illicitly Manufactured Fentanyl–Involved Overdose Deaths with Detected Xylazine — United States, January 2019–June 2022

Increasing presence of xylazine in heroin and/or fentanyl deaths, Philadelphia, Pennsylvania, 2010–2019

Public health impact and harm reduction implications of xylazine-involved overdoses: a narrative review

Xylazine induces dopamine release and augments the effects of fentanyl

The Detection of Xylazine in Tijuana, Mexico: Triangulating Drug Checking and Clinical Urine Testing Data

Xylazine effects on opioid-induced brain hypoxia

Evaluation of the relationship of xylazine and fentanyl blood concentrations among fentanyl-associated fatalities